Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.
暂无分享,去创建一个
[1] Jeroen J. Bax,et al. The universal definition of myocardial infarction , 2015, Oxford Medicine Online.
[2] K. Dickstein,et al. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. , 2013, International journal of cardiology.
[3] F. Mach,et al. Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis. , 2013, Journal of periodontal research.
[4] F. Mach,et al. Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases , 2013, Thrombosis and Haemostasis.
[5] S. Pagano,et al. Auto-antibodies as Emergent Prognostic Markers and Possible Mediators of Ischemic Cardiovascular Diseases , 2013, Clinical Reviews in Allergy & Immunology.
[6] C. Combescure,et al. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy , 2013, Thrombosis and Haemostasis.
[7] M. Burnier,et al. High Prevalence of Anti‐Apolipoprotein/A‐1 Autoantibodies in Maintenance Hemodialysis and Association With Dialysis Vintage , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[8] O. Ratib,et al. Anti-Apolipoprotein A-1 IgG Levels Predict Coronary Artery Calcification in Obese but Otherwise Healthy Individuals , 2012, Mediators of inflammation.
[9] S. Pagano,et al. Anti‐apolipoprotein A‐1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex , 2012, Journal of internal medicine.
[10] P. Libby. Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[11] C. McNamara,et al. Refining the role of B cells in atherosclerosis. , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[12] D. Hochstrasser,et al. Evaluation of cardiovascular risk in patients with rheumatoid arthritis: Do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? , 2012, Arthritis care & research.
[13] D. Hochstrasser,et al. Autoantibodies against apolipoprotein A‐1 and phosphorylcholine for diagnosis of non‐ST‐segment elevation myocardial infarction , 2012, Journal of internal medicine.
[14] T. Lüscher,et al. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.
[15] B. Hahn,et al. Accelerated atherosclerosis in patients with SLE—mechanisms and management , 2012, Nature Reviews Rheumatology.
[16] F. Mach,et al. Head-to-Head Comparison of Auto-Antibodies for Cardiovascular Outcome Prediction after Myocardial Infarction: a Prospective Study , 2011 .
[17] J. Kuiper,et al. Vaccination strategies in atherosclerosis , 2011, Thrombosis and Haemostasis.
[18] M. Pencina,et al. Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. , 2011, Atherosclerosis.
[19] E. Kruithof,et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. , 2011, Blood.
[20] P. Libby,et al. Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.
[21] S. Reddy,et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms , 2011, Nature Reviews Cardiology.
[22] G. Hansson,et al. The immune system in atherosclerosis , 2011, Nature Immunology.
[23] Scott M. Gordon,et al. High density lipoprotein: it's not just about lipid transport anymore , 2011, Trends in Endocrinology & Metabolism.
[24] Soo-Ho Choi,et al. Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity , 2011, Circulation research.
[25] I. Hafström,et al. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity , 2010, Scandinavian journal of rheumatology.
[26] D. Hochstrasser,et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. , 2010, Arthritis and rheumatism.
[27] D. Mikhailidis,et al. The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification , 2010, Current opinion in cardiology.
[28] M. Kaplan. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. , 2010, Rheumatic diseases clinics of North America.
[29] P. Greenland,et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. , 2010, JAMA.
[30] R. Vasan,et al. Review article: Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus , 2010, Diabetes & vascular disease research.
[31] F. Mach,et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. , 2010, European heart journal.
[32] F. Ferrara,et al. High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome , 2010, Lupus.
[33] E. Schwedhelm,et al. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. , 2009, Pharmacological research.
[34] G. Hansson,et al. Vaccination against atherosclerosis? Induction of atheroprotective immunity , 2009, Seminars in Immunopathology.
[35] Wei Zheng,et al. Human Carotid Plaque Calcification and Vulnerability , 2009, Cerebrovascular Diseases.
[36] D. Isenberg,et al. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. , 2008, Rheumatology.
[37] C. Blasi. The autoimmune origin of atherosclerosis. , 2008, Atherosclerosis.
[38] E. Borba,et al. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. , 2008, Swiss medical weekly.
[39] R. Ferrari,et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.
[40] A Hofman,et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. , 2008, JAMA.
[41] J. Chevrolet,et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. , 2008, Clinical science.
[42] G. Hansson,et al. Introduction: Atherosclerosis as inflammation: a controversial concept becomes accepted , 2008, Journal of internal medicine.
[43] S. Appenzeller,et al. Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors , 2008, Current cardiology reviews.
[44] P. Vokonas,et al. Age-Dependent Associations Between Chronic Periodontitis/Edentulism and Risk of Coronary Heart Disease , 2008, Circulation.
[45] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[46] Robert H Christenson,et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.
[47] D. Isenberg,et al. Antibodies toward High‐Density Lipoprotein Components Inhibit Paraoxonase Activity in Patients with Systemic Lupus Erythematosus , 2007, Annals of the New York Academy of Sciences.
[48] Erling Falk,et al. Plaque rupture in humans and mice. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[49] M. Pfeffer,et al. Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.
[50] D. Morrow,et al. Benchmarks for the Assessment of Novel Cardiovascular Biomarkers , 2007, Circulation.
[51] E. Kruithof,et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. , 2007, Blood.
[52] A. Hamsten,et al. Lower serum concentration of matrix metalloproteinase‐3 in the acute stage of myocardial infarction , 2006, Journal of internal medicine.
[53] S. Yokota,et al. Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. , 2006, International immunology.
[54] Y. Shoenfeld,et al. Intravenous immunoglobulin and atherosclerosis , 2005, Clinical reviews in allergy & immunology.
[55] J. Borén,et al. Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E–/– low‐density lipoprotein receptor –/– mice via the complement system , 2005, Clinical and experimental immunology.
[56] T. Kita,et al. Effects of late administration of immunoglobulin on experimental atherosclerosis in apolipoprotein E-deficient mice. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[57] Paolo Raggi,et al. Detection of high-risk young adults and women by coronary calcium and National Cholesterol Education Program Panel III guidelines. , 2005, Journal of the American College of Cardiology.
[58] Jason L. Johnson,et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[59] Jean-Claude Tardif,et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. , 2005, European heart journal.
[60] M. Hersberger,et al. Inflammatory Markers at the Site of Ruptured Plaque in Acute Myocardial Infarction: Locally Increased Interleukin-6 and Serum Amyloid A but Decreased C-Reactive Protein , 2005, Circulation.
[61] J. Dayer,et al. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. , 2004, Journal of autoimmunity.
[62] R. Kahn,et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for theAmerican Cancer Society, the American Diabetes Association, and the American Heart Association. , 2004, CA: a cancer journal for clinicians.
[63] Tom Fahey,et al. Predictive accuracy of the Framingham coronary risk score in British men:prospective cohort study , 2003, BMJ : British Medical Journal.
[64] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.
[65] D. Isenberg,et al. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. , 2003, Rheumatology.
[66] D. Isenberg,et al. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. , 2002, Arthritis and rheumatism.
[67] H. Sakuraba,et al. Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. , 2001, The Journal of rheumatology.
[68] S. Nitter‐Hauge,et al. Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.
[69] M. Burnett,et al. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[70] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[71] A. Rebuzzi,et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.
[72] J. Merrill,et al. Fequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE , 1998, Lupus.
[73] R. Virmani,et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. , 1997, The New England journal of medicine.
[74] D. Stafforini,et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.
[75] J. Merrill,et al. Selection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus. , 1995, Arthritis and rheumatism.
[76] G. Hansson,et al. Detection of activated T lymphocytes in the human atherosclerotic plaque. , 1989, The American journal of pathology.
[77] R S Paffenbarger,et al. Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.
[78] Brian Parks,et al. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. , 2011, Arthritis and rheumatism.
[79] P. Toth. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability , 2011 .
[80] John Andersson,et al. Adaptive immunity and atherosclerosis. , 2010, Clinical immunology.
[81] Peter Libby,et al. Inflammation in Atherosclerosis : From Vascular Biology to Biomarker Discovery and Risk Prediction , 2007 .
[82] Yoram Rudy,et al. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. , 2006, The American journal of cardiology.
[83] A. Naylor,et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. , 2000, Stroke.